BrainStorm Cell Therapeutics Announces Full Year 2022 Financial Results and Provides a Corporate Update

Biologics License Application for NurOwn® for the treatment of ALS to be discussed in an upcoming FDA Advisory Committee Meeting Conference call and webcast at 8:00 a.m. Eastern Time today NEW YORK, March 30, 2023 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading…